Showing 1 - 20 results of 47 for search '"ДЕГИДРОЭПИАНДРОСТЕРОН"', query time: 0.64s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
    Academic Journal

    Contributors: Исследование проведено в рамках выполнения государственного задания учреждения. Работа выполнена с использованием оборудования ЦКП «Протеомный анализ», поддержанного финансированием Минобрнауки России (соглашение № 07515-2021-691).

    Source: Acta Biomedica Scientifica; Том 7, № 4 (2022); 52-61 ; 2587-9596 ; 2541-9420

    File Description: application/pdf

    Relation: https://www.actabiomedica.ru/jour/article/view/3644/2383; Баланова Ю.А., Концевая А.В., Мырзаматова А.О., Муканеева Д.К., Худяков М.Б., Драпкина О.М. Экономический ущерб от артериальной гипертонии, обусловленный её вкладом в заболеваемость и смертность от основных хронических неинфекционных заболеваний в Российской Федерации. Рациональная фармакотерапия в кардиологии. 2020; 16(3): 415-423. doi:10.20996/1819-6446-2020-05-03; Денисова А.Р., Солнцева Т.Д., Сивакова О.А., Чазова И.Е. Неконтролируемая артериальная гипертония: основные причины, особенности патогенеза и подходы к лечению. Системные гипертензии. 2021; 18(1): 13-18. doi:10.26442/20750 82X.2021.1.200724; Colafella KMM, Denton KM. Sex-specific differences in hypertension and associated cardiovascular disease. Nat Rev Nephrol. 2018; 14(3): 185-201. doi:10.1038/nrneph.2017.189; Лебедева Н.Б., Гофман В.В. Взаимосвязь возрастного гипогонадизма с риском развития сердечно-сосудистых заболеваний. Фундаментальная и клиническая медицина. 2020; 5(2): 60-66. doi:10.23946/2500-0764-2020-5-2-60-66; Zhang J, Li X, Cai Z, Li H, Yang B. Association between testosterone with type 2 diabetes in adult males, a meta-analysis and trial sequential analysis. Aging Male. 2019; 23(5): 607-618. do i: 10.1080/13685538.2018.1557139; Тюзиков И.А. Дегидроэпиандростерон у мужчин: потенциальные физиологические эффекты с позиции доказательной медицины. Эффективная фармакотерапия. 2020; 16(20): 44-51. doi:10.33978/2307-3586-2020-16-20-44-51; Park M, Kim S, Won Y. Relationship between testosterone deficiency and the cardiovascular risk factors, diabetes and hypertension. J Mens Health. 2020; 16(4): 97-109. doi:10.31083/jomh.v16i4.328; Bianchi VE.Testosterone, myocardial function, and mortality.Heart Fail Rev. 2018; 23(5): 773-788. doi:10.1007/s10741-018-9721-0; Попов П.С., Курникова И.А., Торшин В.И., Малютина Н.Н. Состояние липидного обмена у пациентов, получающих андрогензаместительную терапию. Пермский медицинский журнал. 2020; 37(5): 20-26. doi:10.17816/pmj37520-26; Зеленина Т.А., Салухов В.В., Земляной А.Б., Чебыкина О.Е. Заместительная гормональная терапия тестостероном у мужчин с сахарным диабетом 2 типа и нейропатией. Фарматека. 2021; 28(4): 55-61. doi:10.18565/pharmateca.2021.4.55-60; Ghadimi R, Khalilipour A, Malekian N, Esmaili H, Hosseini SR, Bayani M. Serum testosterone and metabolic syndrome in old-aged males: preliminary findings of the AHAP cohort study. Rom JDiabetes Nutr Metab Dis. 2020; 27(3): 245-250. doi:10.46389/rjd-2020-1036; Лебедева Н.Б., Гофман В.В. Современные представления о роли возрастного гипогонадизма в развитии сердечнососудистых заболеваний. Терапевтический архив. 2021; 93(1): 79-83. doi:10.26442/00403660.2021.01.200597; Bavishi A, Patel RB. Addressing comorbidities in heart failure: Hypertension, atrial fibrillation, and diabetes. Heart Fail Clin. 2020; 16(4): 441-456. doi:10.1016/j.hfc.2020.06.005; Xu X, Wang L, Luo D, Zhang M, Chen S, Wang Y, et al. Effect of testosterone synthesis and conversion on serum testosterone levels in obese men. Horm Metab Res. 2018; 50(09): 661-670. doi:10.1055/a-0658-7712; Pinkhasov BB, Selyatitskaya VG, Karapetyan AR, Astrakhantseva EL. Metabolic syndrome in men and women with upper or lower types of body fat distribution. Health. 2012; 4(12A): 13811389. doi:10.4236/health.2012.412A200; Мустафина С.В., Малютина С.К., Рымар О.Д., Щербакова Л.В., Bobak М., Воевода М.И. Эпидемиология ожирения и развитие нарушений углеводного обмена по данным проспективного исследования в Сибири. Ожирениеиметаболизм. 2015; 12(4): 24-28. doi:10.14341/omet2015424-28; Mendoza MF, Kachur SM, Lavie CJ. Hypertension in obesity. Curr Opin Cardiol. 2020; 35(4): 389-396. doi:10.1097/HCO.0000000000000749; Ke C, Zhu X, Zhang Y, Shen Y. Metabolomic characterization of hypertension and dyslipidemia. Metabolomics. 2018; 14(9): 117. doi:10.1007/s11306-018-1408-y; Lee JS, Chang PY, Zhang Y, Kizer JR, Best LG, Howard BV. Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: the strong heart study. Diabetes care. 2017; 40(4): 529-537. doi:10.2337/dc16-1958; Yildiz M, Oktay AA, Stewart MH, Milani RV, Ventura HO, Lavie CJ. Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis. 2020; 63(1): 10-21. doi:10.1016/j.pcad.2019.11.009; Slivnick J, Lampert BC. Hypertension and heart failure. Heart Fail Clin. 2019; 15(4): 531-541. doi:10.1016/j.hfc.2019.06.007; Dzeshka MS, Shantsila A, Shantsila E, Lip GY. Atrial fibrillation and hypertension. Hypertension. 2017; 70(5): 854-861. doi:10.1161/HYPERTENSIONAHA.117.08934; Selyatitskaya VG, Epanchintseva EA, Novikova EG, Shilina NI, Pinkhasov BB. Hormonal characteristics of androgen status in males of different age groups. Advances in Gerontology. 2020; 10(3): 210-214. doi:10.1134/S2079057020030169; Salama N, Blgozah S. Serum estradiol levels in infertile men with non-obstructive azoospermia. Ther Adv Reprod Health. 2020; 14: 2633494120928342. doi:10.1177/2633494120928342; Van Hemelrijck M, Sollie S, Nelson WG, Yager JD, Kanarek NF, Dobs A, et al. Selenium and sex steroid hormones in a US nationally representative sample of men: A role for the link between selenium and estradiol in prostate carcinogenesis? Cancer Epidemiol Biomarkers Prev. 2019; 28(3): 578-583. doi:10.1158/10559965.EPI-18-0520; Bellastella G, Menafra D, Puliani G, Colao A, Savastano S. How much does obesity affect the male reproductive function? Int JObes Suppl. 2019; 9(1): 50-64. doi:10.1038/s41367-019-0008-2; Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Роживанов Р.В., Камалов А.А., Мкртумяни А.М. и др. Проект клинических рекомендаций «синдром гипогонадизма у мужчин». Ожирение и метаболизм. 2021; 18(4): 496-507. doi:10.14341/omet12817; Терещенко С.Н., Галявич А.С., Ускач Т.М., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020; 25(11): 311-374. doi:10.15829/1560-4071-2020-4083; Дедов И.И., Шестакова М.В., Майоров А.Ю., Шамхалова М.Ш., Сухарева О.Ю., Галстян Г.Р. и др. Сахарный диабет 2 типа у взрослых. Сахарныйдиабет. 2020; 23(S2): 4-102. doi:10.14341/DM20202S; Mannella P, Simoncini T, Caretto M, Genazzani AR. Dehydroepiandrosterone and cardiovascular disease. Vitam Horm. 2018; 108: 333-353. doi:10.1016/bs.vh.2018.05.001; Yoshida S, Aihara KI, Azuma H, Uemoto R, Sumitomo-Ueda Y, Yagi S, et al. Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis. 2010; 212(1): 310-315. doi:10.1016/j.atherosclerosis.2010.05.011; Wang F, He Y, Santos HO, Sathian B, Price JC, Diao J. The effects of dehydroepiandrosterone (DHEA) supplementation on body composition and blood pressure: A meta-analysis of randomized clinical trials. Steroids. 2020; 163: 108710. doi:10.1016/j.steroids.2020.108710; Sahu P, Gidwani B, Dhongade HJ. Pharmacological activities of dehydroepiandrosterone: A review. Steroids. 2020; 153: 108507. doi:10.1016/j.steroids.2019.108507; https://www.actabiomedica.ru/jour/article/view/3644

  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
    Academic Journal

    Source: Andrology and Genital Surgery; Том 16, № 1 (2015); 13-22 ; Андрология и генитальная хирургия; Том 16, № 1 (2015); 13-22 ; 2412-8902 ; 2070-9781 ; 10.17650/2070-9781-2015-1

    File Description: application/pdf

    Relation: https://agx.abvpress.ru/jour/article/view/126/120; Butenandt A., Dannenbaum H. Isolierung eines neuen physiologisch unwirksamen sterinderivats aus mannerharn, seine verknupfung mit dehydroandrosteron und androsteron. Z Physiol Chem 1934;229:192–5.; Munson P.L., Gallagher T.F., Koch F.C. Isolation of dehydroisoandrosterone sulfate from normal male urine. J Biol Chem 1944;152(1):67–77.; Migeon C.J., Plager J.E. Identification and isolation of dehydroisoandrosterone sulfate from peripheral human plasma. J Biol Chem 1954;209(2):767–72.; Baulieu E.E. Three sulfate esters of 17-ketosteroids in the plasma of human subjects after administration of ACTH. J Clin Endocrinol Metab 1960;20:900–4.; Baulieu E.E., Corpechot C., Dray F. et al. An adrenal secreted “androgen”: dehydroisoandrosterone sulfate. Its metabolism and a tentative generalization on the metabolism of other steroid conjugates in man. Recent Prog Horm Res 1965;21:411–500.; Гончаров Н.П. Функция коры надпочечников у низших обезьян в норме и при некоторых патологических состояниях. Дис. . д-ра мед. наук. Сухуми, 1971. [Goncharov N.P. Function of the adrenal cortex of monkeys in normal and pathological conditions. Thesis . of doctor of medical scienses. Sukhumi, 1971. (In Russ.)].; Leinonen P., Ruokonen A., Kontturi M., Vihko R. Effects of estrogen treatment on human testicular unconjugated steroid and steroid sulfate production in vivo. J Clin Endocrinol Metab 1981;53(3):569–73.; McKenna T.J., DiPietro D.L., Brown R.D. et al. Plasma 17-OHpregnenolone in normal subjects. J Clin Endocrinol Metab 1974;39(5):833–41.; Baulieu E.E., Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J Endocrinol 1996;150(Suppl):S221–39.; Goncharov N.P., Katsiya G.V., Dzhokua A.A. et al. Effect of neurosteroid dehydroepiandrosterone on the higher nervous activity of old non-human primates. Hum Physiol 2014;40(2):149–55.; Belanger A., Candas B., Dupont A. et al. Changes in serum concentrations of conjugated and unconjugated steroids in 40to 80-year-old men. J Clin Endocrinol Metab 1994;79(4):1086–90.; Rotter J.I., Wong F.L., Lifrak E.T., Parker L.N. A genetic component to the variation of dehydroepiandrosterone sulfate. Metabolism 1985;34(8):731–6.; Birkenhager-Gillesse E.G., Derksen J., Lagaay A.M. Dehydroepiandrosterone sulphate (DHEAS) in the oldest old, aged 85 and over. Ann NY Acad Sci 1994;719:543–52.; Field A.E., Colditz G.A., Willett W.C. et al. The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormonebinding globulin in middle-aged men. J Clin Endocrinol Metab 1994;79(5):1310–6.; Thomas G., Frenoy N., Legrain S. et al. Serum dehydroepiandrosterone sulfate levels as an individual marker. J Clin Endocrinol Metab 1994;79(5):1273–6.; Rosenfeld R.S., Rosenberg B.J., Fukushima D.K., Hellman L. 24-Hour secretary pattern of dehydroisoandrosterone and dehydroisoandrosterone sulfate. J Clin Endocrinol Metab 1975;40(5):850–5.; Гончаров Н.П., Колесникова. Г.С. Кортикостероиды: метаболизм, механизм действия и клиническое применение. М.: АдамантЪ, 2002. С. 62–75. [Goncharov N.P., Kolesnikova G.S. Corticos teroids: metabolism, mechanisms of action, and clinical application. Moscow: Adamant, 2002. Pp. 62–75. (In Russ.)].; Zumoff B., Rosenfeld R.S., Strain G.W. et al. Sex differences in the twenty-four-hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adults. J Clin Endocrinol Metab 1980;51(2):330–3.; Watanabe S., Tani T., Watanabe S., Seno M. Effects of free fatty acids on the binding of steroid hormones to bovine serum albumin. Lipids 1990;25(10):633–8.; Goncharov N.P., Katzya G.V. Adrenal and gonadal steroid levels in long-living males from highland regions of the Southwestern Caucasian Mountains. Aging Male 1998;1:200–5.; Bird C.E., Masters V., Clark A.F. Dehydroepiandrosterone sulfate: kinetics of metabolism in normal young men and women. Clin Invest Med 1984;7(2):119–22.; Haning R.V. Jr, Chabot M., Flood C.A. et al. Metabolic clearance rate (MCR) of dehydroepiandrosterone sulfate (DS), its metabolism to dehydroepiandrosterone, androstenedione, testosterone, and dihydrotestosterone, and the effect of increased plasma DS concentration on DS MCR in normal women. J Clin Endocrinol Metab 1989;69(5):1047–52.; MacDonald P.C. et al. Plasma precursors of estrogen. III. Conversion of plasma dehydroisoandrosterone to estrogen in young nonpregnant women. Gynecol Invest 1976; 7(3):165–75.; Horton R., Tait J.F. In vivo conversion of dehydroisoandrosterone to plasma androstenedione and testosterone in man. J Clin Endocrinol Metab 1967;27(1):79–88.; Poortman J. et al. Interaction of delta-5androstene-3beta, 17beta-diol with estradiol and dihydrotestosterone receptors in human myometrial and mammary cancer tissue. J Clin Endocrinol Metab 1975;40(3):373–9.; Labrie F., Dupont A., Belanger A. et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982;5(4):267–75.; Khalil M.W., Strutt B., Vachon D., Killinger D.W. Effect of dexamethasone and cytochrome P450 inhibitors on the formation of 7alpha-hydroxydehydroepiandrosterone by human adipose stromal cells. J Steroid Biochem Mol Biol 1994;48(5–6):545–52.; Luu-The V., Dufort I., Paquet N. et al. Structural characterization and expression of the human dehydroepiandrosterone sulfotransferase gene. DNA Cell Biol 1995;14(6):511–8.; Rheaume E., Simard J., Morel Y. et al. Congenital adrenal hyperplasia due to point mutations in the type II 3 betahydroxysteroid dehydrogenase gene. Nat Genet 1992;1(4):239–45.; Labrie F., Sugimoto Y., Luu-The V. et al. Structure of human type II 5 alpha-reductase gene. Endocrinology 1992;131(3):1571–3.; Labrie F., Simard J., Luu-The V. et al. Structure and tissue-specific expression of 3 beta-hydroxysteroid dehydrogenase/ 5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues. J Steroid Biochem Mol Biol 1992;41(3–8):421–35.; Luu-The V., Zhang Y., Poirier D., Labrie F. Characteristics of human types 1, 2 and 317 beta-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J Steroid Biochem Mol Biol 1995;55(5– 6):581–7.; Labrie Y., Durocher F., Lachance Y. et al. The human type II 17 beta-hydroxysteroid dehydrogenase gene encodes two alternatively spliced mRNA species. DNA Cell Biol 1995;14(10):849–61.; Labrie F., Simard J., Luu-The V. The 3-beta-hydroxysteroid dehydrogenase/ isomerase gene family: lessions from type II 3beta-HSD congenital deficiency. In: V. Hansson, F.O. Levy, K. Tasken (eds.). Signal transduction in testicular cells. Ernst Schering Research Foundation Workshop. Berlin, Heidelberg, New York: SpringerVerlag, 1996. Pp. 185–218.; Stahl F., Schnorr D., Pilz C., Dörner G. Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress. Exp Clin Endocrinol 1992;99(2):68–70.; Zumoff B., Levin J., Rosenfeld R.S. et al. Abnormal 24-hr mean plasma concentrations of dehydroisoandrosterone and dehydroisoandrosterone sulfate in women with primary operable breast cancer. Cancer Res 1981;41(9 Pt 1):3360–3.; Schwartz A.G., Pashko L., Whitcomb J.M. Inhibition of tumor development by dehydroepiandrosterone and related steroids. Toxicol Pathol 1986;14(3):357–62.; Gordon G.B., Shantz L.M., Talalay P. Modulation of growth, differentiation and carcinogenesis by dehydroepiandrosterone. Adv Enzyme Regul 1987;26:355–82.; Li S., Yan X., Belanger A., Labrie F. Prevention by dehydroepiandrosterone of the development of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene (DMBA) in the rat. Breast Cancer Res Treat 1994;29(2):203–17.; Casson P.R., Andersen R.N., Herrod H.G. et al. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 1993;169(6):1536–9.; Morales A.J., Nolan J.J., Nelson J.C., Yen S.S. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994;78(6):1360–7.; Diamond P., Cusan L., Gomez J.L. et al. Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol 1996;150(Suppl):S43–50.; Bolander F.F. Molecular endocrinology. San Diego, London: Academic Press, 1996. Pp. 1–23.; Labrie C., Martel C., Dufour J.M. et al. Novel compounds inhibit estrogen formation and action. Cancer Res 1992;52(3):610–5.; Luo S., Sourla A., Labrie C. et al. Effect of twenty-four-week treatment with the antiestrogen EM-800 on estrogensensitive parameters in intact and ovariectomized mice. Endocrinology 1998;139(5):2645–56.; Luu-The V., Labrie C., Simard J. et al. Structure of two in tandem human 17 betahydroxysteroid dehydrogenase genes. Mol Endocrinol 1990;4(2):268–75.; Labrie F., Bélanger A., Simard J. et al. DHEA and peripheral androgen and estrogen formation: intracinology. Ann NY Acad Sci 1995;774:16–28.; Studd J.W. et al. Plasma hormone profiles after the menopause and bilateral oophorectomy. Postgrad Med J 1978;54 Suppl 2:25–30.; Longcope C., Hui S.L., Johnston C.C. Jr. Free estradiol, free testosterone, and sex hormone-binding globulin in perimenopausal women. J Clin Endocrinol Metab 1987;64(3):513–8.; Steinberg K.K., Freni-Titulaer L.W., DePuey E.G. et al. Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab 1989;69(3):533–9.; Labrie C., Flamand M., Bélanger A., Labrie F. High bioavailability of dehydroepiandrosterone administered percutaneously in the rat. J Endocrinol 1996;150(Suppl):S107–18.; Labrie F., Bélanger A., Cusan L., Candas B. Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 1997;82(8):2403–9.; Huggins C., Hodges C.V. Studies on prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1(4):293–7.; Гончаров Н.П. Антиандрогены и их применение при раке предстательной железы. Андрология и генитальная хирургия 2002;(2):40–9. [Goncharov N.P. Antiandrogens and their use with, prostate cancer. Andrologiya i genital naya khirurgiya = Andrology and Genital Surgery 2002; (2):40–9. (In Russ.)].; Neri R., Florance K., Koziol P., Van Cleave S. A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4,–nitro-3,trifluoromethylisobutyranilide). Endocrinology 1972;91(2):427–37.; Гончаров Н.П., Кация Г.В. Гормон здоровья и долголетия. М.: АдамантЪ, 2012. 159 с. [Goncharov N.P., Katsiya G.V. Hormone of health and longevity. Moscow: Adamant, 2012. 159 p. (In Russ.)].; Cohen H.N., Hay I.D., Beastall G.H., Thomson J.A. Failure of adrenal androgen to induce puberty in familial cytomegalic adrenocortical hypoplasia. Lancet 1982;2(8313):1471–2.; Nestler J.E., Barlascini C.O., Clore J.N., Blackard W.G. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 1988;66(1):57–61.; Buster J.E., Casson P.R., Straughn A.B. et al. Postmenopausal steroid replacement with micronized dehydroepiandrosterone: preliminary oral bioavailability and dose proportionally studies. Am J Obstet Gynecol 1992;166(4):1163–8.; Casson P.R., Straughn A.B., Umstot E.S. et al. Delivery of dehydroepiandrosterone to premenopausal women: effects of micronization and nonoral administration. Am J Obstet Gynecol 1996;174(2):649–53.; Casson P.R., Faquin L.C., Stentz F.B. et al. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril 1995;63(5):1027–31.; Casson P.R., Santoro N., Elkind-Hirsch K. et al. Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a sixmonth trial. Fertil Steril 1998;70(1):107–10.; Labrie F., Diamond P., Cusan L. et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997;82(10):3498–505.; https://agx.abvpress.ru/jour/article/view/126

  11. 11
    Academic Journal

    Source: Andrology and Genital Surgery; Том 16, № 3 (2015); 40-43 ; Андрология и генитальная хирургия; Том 16, № 3 (2015); 40-43 ; 2412-8902 ; 2070-9781 ; 10.17650/2070-9781-2015-16-3

    File Description: application/pdf

    Relation: https://agx.abvpress.ru/jour/article/view/154/147; Аляев Ю.Г., Амосов А.В., Безруков Е.А., Бутнару Д.В. Пищевые антиоксиданты и фитоэстрогены в профилактике рака простаты: результаты последних исследований. Consilium medicum 2009; (7):63–5. [Alyayev Yu.G., Amosov A.V., Bezrukov E.A., Butnaru D.V. Dietary antioxidants and phytoestrogens in prevention of the prostate cancer: results of latest studies. Consilium Medicum 2009;(7):63–5. (In Russ.)].; Состояние онкологической помощи населению России в 2010 году. Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2011. [Status of oncology aid to the population of Russia in 2010. Ed. by V.I. Chissov, V.V. Starinskiy, G.V. Petrova. Moscow, 2011. (In Russ.)].; Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1(4):293–7.; Mcleod D.G. Hormonal therapy: historical perspective to future directions. Urology 2003;61 (2 Suppl 1):3–7.; Gravanis I., Lopez A.S., Hemmings R.J. et al. The European medicines agency review of abiraterone for the treatment of metastatic castration-resistant prostate cancer in adult men after docetaxel chemotherapy and in chemotherapy-naïve disease: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 2013;18(9):1032–42.; Stein M.N., Goodin S., DiPaola R.S. Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res 2012;18(7):1848–54; Stein M.N., Patel N., Bershadskiy A. et al. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl 2014;16(3):387–400.; Burgio S.L., Conteduca V., Rudnas B. et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2015;13(1):39–43.; https://agx.abvpress.ru/jour/article/view/154

  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20